GLP-1 Drugs and Alcohol: Why Researchers Are Taking the Evidence More Seriously

A review published in the Journal of Clinical Investigation in September 2026 brings together growing evidence that GLP-1-targeted medicines may reduce alcohol consumption — and potentially affect other substance-use disorders. Controlled human trial data now exists, though researchers are clear it is early and limited. Here is what the evidence actually shows, and what it does not yet prove.

For several years, people taking weight-loss medicines such as semaglutide (Ozempic, Wegovy) have been reporting something unexpected: they seem to want alcohol less. The drinks they used to enjoy feel less appealing. Some describe losing interest in alcohol almost entirely. Scientists have been trying to work out whether this is real, and if so, why.

A review published in the Journal of Clinical Investigation in September 2026 examines the growing body of evidence that GLP-1-targeted therapies — medicines that work on the glucagon-like peptide-1 signalling system — may influence alcohol consumption and other substance-use disorders. It marks a significant moment in what has become one of the more unexpected research questions in modern medicine.

The Key Controlled Human Trial

The most important piece of controlled human evidence published to date comes from a Phase 2 double-blind, randomised, placebo-controlled trial published in JAMA Psychiatry on 12 February 2025. Researchers randomised 48 non-treatment-seeking adults with alcohol-use disorder to receive either low-dose semaglutide or a placebo over nine weeks.

The results showed that semaglutide reduced the amount of alcohol participants consumed during a controlled laboratory alcohol self-administration test, compared with placebo. Semaglutide also significantly reduced drinks per drinking day and weekly alcohol craving, and produced greater relative reductions in heavy drinking over time.

However, the results were not uniformly positive across every measure. Semaglutide did not significantly reduce average drinks per calendar day or the total number of drinking days. The researchers were clear that the findings justify larger clinical trials but do not establish semaglutide as an effective treatment for alcohol-use disorder. This was a small Phase 2 study involving 48 adults, and it should be understood as an early encouraging signal rather than a conclusive answer.

Earlier Human Evidence and Observational Research

The 2025 JAMA Psychiatry trial was not the first controlled human study to explore this question. Earlier research examined exenatide — another GLP-1 receptor agonist — in people with alcohol-use disorder, providing preliminary human evidence that GLP-1 signalling might influence drinking behaviour.

Alongside the controlled trials, several large observational studies using health records and other real-world datasets have reported associations between GLP-1 agonist use and reduced alcohol consumption or fewer alcohol-related events. Observational evidence cannot establish cause and effect on its own, but when it aligns with results from controlled trials and with preclinical research, it adds to the overall picture.

What the Animal and Laboratory Evidence Suggests

The scientific interest in GLP-1 drugs and alcohol did not begin with patient reports. Preclinical research in animal models has repeatedly found that GLP-1 receptor agonists can reduce voluntary alcohol intake. Laboratory research suggests that GLP-1 signalling interacts with the brain’s reward and motivation pathways — including dopamine signalling — in ways that may reduce the reinforcing effects of alcohol.

This proposed mechanism is biologically plausible: GLP-1 receptors are found in brain regions involved in reward processing, including the nucleus accumbens and ventral tegmental area. But plausibility is not proof, and animal findings do not automatically translate to humans.

A Genuine Effect or a Side Effect?

One important question the research is still working through is whether reduced drinking reflects a direct effect of GLP-1 signalling on alcohol-related reward, or whether it is partly explained by other treatment effects. Semaglutide can cause nausea, particularly during dose escalation. It also significantly reduces appetite and food intake. Either effect could potentially influence someone’s desire to drink alcohol.

The 2025 trial used relatively low doses of semaglutide and still found reductions in laboratory alcohol consumption and some measures of craving and drinking. This supports further investigation, but it does not establish exactly why the effect occurred. The mechanism has not been definitively resolved, and it matters for understanding whether any effect would generalise across different medicines and doses.

What About Tirzepatide and Other GLP-1 Medicines?

Most of the controlled human evidence relates to semaglutide specifically. Tirzepatide (Mounjaro), which targets both GLP-1 and GIP receptors, is a different medicine with a different receptor profile. It would be wrong to assume that findings from semaglutide trials automatically apply to tirzepatide or to other incretin-based medicines such as retatrutide.

Some observational data has included tirzepatide users, but controlled trial evidence examining tirzepatide specifically in alcohol-use disorder remains limited. Researchers working in this area are careful to distinguish between medicines rather than treating all GLP-1-related drugs as interchangeable. Readers curious about retatrutide should be aware that evidence for that medicine in this context is even more preliminary.

What the UK Regulatory Position Is

No GLP-1 medicine is currently licensed in the UK by the MHRA for the treatment of alcohol-use disorder or any other substance-use disorder. In the UK, semaglutide is licensed for type 2 diabetes management and, in the form of Wegovy, for weight management in adults meeting specific criteria. Tirzepatide is licensed as Mounjaro for type 2 diabetes and weight management. Neither licence covers alcohol-use disorder.

GLP-1 medicines are not currently established NHS treatments for alcohol-use disorder, and NICE has not recommended them for this purpose. Larger confirmatory trials would be needed before these medicines could become established treatments for alcohol-use disorder.

What This Means For UK Patients

If you are already taking a GLP-1 medicine for weight management and have noticed you are drinking less or finding alcohol less appealing, your experience is consistent with reports that researchers are now actively investigating. There may be a biological basis for the effect, although scientists have not yet fully explained the mechanism or established how reliable or lasting it is.

What the evidence does not currently support is treating GLP-1 medicines as established treatments for alcohol-use disorder. No GLP-1 medicine is licensed for this purpose in the UK, and the evidence base — while genuinely promising — remains early and limited.

If you are concerned about your drinking, the most useful starting point remains a conversation with your GP. NHS alcohol support services and specialist treatment are available, depending on individual circumstances. The research into GLP-1 drugs and alcohol is genuinely interesting, but it is not yet ready to be translated into a clinical recommendation. Larger trials are needed to establish whether the early findings translate into an effective and safe treatment.

For readers who want to understand more about how approved GLP-1 medicines currently work in the UK, the weight-loss jabs guide provides a clear, up-to-date overview.

Frequently Asked Questions

Do GLP-1 medicines reduce alcohol cravings?

A randomised controlled trial published in JAMA Psychiatry in February 2025 found that low-dose semaglutide significantly reduced weekly alcohol craving and drinks per drinking day compared with placebo in adults with alcohol-use disorder. However, it did not significantly reduce all measures of drinking, and this was a small 48-person Phase 2 study. Larger trials are needed before firm conclusions can be drawn.

Can I use Ozempic or Wegovy to help cut down on alcohol?

Semaglutide is not licensed by the MHRA for alcohol-use disorder, and it is not an established NHS treatment for this purpose. The research is promising but remains at an early stage. If you are concerned about your alcohol use or want help reducing it, speak to your GP about established treatment and support options.

Does tirzepatide (Mounjaro) have the same effect on alcohol as semaglutide?

There is currently no strong controlled trial evidence showing that tirzepatide reduces alcohol consumption in the same way as semaglutide. The two medicines work differently. Some observational data includes tirzepatide users, but it would be wrong to assume that semaglutide findings automatically apply to Mounjaro.

Why might GLP-1 medicines affect alcohol consumption?

One proposed explanation is that GLP-1 receptors are present in brain regions involved in reward and motivation, and activating them may alter the rewarding effects of alcohol. But whether reduced drinking reflects this direct brain mechanism, or is partly explained by treatment-related nausea, reduced appetite or other changes, has not been definitively established. More than one mechanism may be involved.

Is this research area likely to lead to a licensed treatment?

Possibly, but considerably more evidence is needed. Larger and longer clinical trials are the necessary next step. Any future licensing decision would depend on those studies demonstrating sufficient safety and effectiveness. No GLP-1 medicine is currently licensed in the UK for alcohol-use disorder.